Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway

L. Bizzozero, D. Cazzato, D. Cervia, E. Assi, F. Simbari, F. Pagni, C. De Palma, A. Monno, C. Verdelli, P. R. Querini, V. Russo, E. Clementi, C. Perrotta

Research output: Contribution to journalArticle

Abstract

Melanoma is a rapidly growing and highly metastatic cancer with high mortality rates, for which a resolutive treatment is lacking. Identification of novel therapeutic strategies and biomarkers of tumour stage is thus of particular relevance. We report here on a novel biomarker and possible candidate therapeutic target, the sphingolipid metabolising enzyme acid sphingomyelinase (A-SMase). A-SMase expression correlates inversely with tumour stage in human melanoma biopsies. Studies in a mouse model of melanoma and on cell lines derived from mouse and human melanomas demonstrated that A-SMase levels of expression actually determine the malignant phenotype of melanoma cells in terms of pigmentation, tumour progression, invasiveness and metastatic ability. The action of A-SMase is mediated by the activation of the extracellular signal-regulated kinase, the subsequent proteasomal degradation of the Microphtalmia-associated transcription factor (Mitf) and inhibition of cyclin-dependent kinase 2, Bcl-2 and c-Met, downstream targets of Mitf involved in tumour cell proliferation, survival and metastatisation.

Original languageEnglish
Pages (from-to)507-520
Number of pages14
JournalCell Death and Differentiation
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 2014

Fingerprint

Sphingomyelin Phosphodiesterase
Melanoma
Transcription Factors
Acids
Neoplasms
Cyclin-Dependent Kinase 2
Sphingolipids
Aptitude
Extracellular Signal-Regulated MAP Kinases
Pigmentation
Tumor Biomarkers
Cell Survival
Biomarkers
Cell Proliferation
Phenotype
Biopsy
Cell Line
Mortality
Enzymes
Therapeutics

Keywords

  • acid sphingomyelinase
  • melanoma
  • microphtalmia- associated transcription factor
  • signalling mechanisms

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway. / Bizzozero, L.; Cazzato, D.; Cervia, D.; Assi, E.; Simbari, F.; Pagni, F.; De Palma, C.; Monno, A.; Verdelli, C.; Querini, P. R.; Russo, V.; Clementi, E.; Perrotta, C.

In: Cell Death and Differentiation, Vol. 21, No. 4, 04.2014, p. 507-520.

Research output: Contribution to journalArticle

Bizzozero, L, Cazzato, D, Cervia, D, Assi, E, Simbari, F, Pagni, F, De Palma, C, Monno, A, Verdelli, C, Querini, PR, Russo, V, Clementi, E & Perrotta, C 2014, 'Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway', Cell Death and Differentiation, vol. 21, no. 4, pp. 507-520. https://doi.org/10.1038/cdd.2013.173
Bizzozero, L. ; Cazzato, D. ; Cervia, D. ; Assi, E. ; Simbari, F. ; Pagni, F. ; De Palma, C. ; Monno, A. ; Verdelli, C. ; Querini, P. R. ; Russo, V. ; Clementi, E. ; Perrotta, C. / Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway. In: Cell Death and Differentiation. 2014 ; Vol. 21, No. 4. pp. 507-520.
@article{5c8fa0b9efa34a1a805e2d44e58261e9,
title = "Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway",
abstract = "Melanoma is a rapidly growing and highly metastatic cancer with high mortality rates, for which a resolutive treatment is lacking. Identification of novel therapeutic strategies and biomarkers of tumour stage is thus of particular relevance. We report here on a novel biomarker and possible candidate therapeutic target, the sphingolipid metabolising enzyme acid sphingomyelinase (A-SMase). A-SMase expression correlates inversely with tumour stage in human melanoma biopsies. Studies in a mouse model of melanoma and on cell lines derived from mouse and human melanomas demonstrated that A-SMase levels of expression actually determine the malignant phenotype of melanoma cells in terms of pigmentation, tumour progression, invasiveness and metastatic ability. The action of A-SMase is mediated by the activation of the extracellular signal-regulated kinase, the subsequent proteasomal degradation of the Microphtalmia-associated transcription factor (Mitf) and inhibition of cyclin-dependent kinase 2, Bcl-2 and c-Met, downstream targets of Mitf involved in tumour cell proliferation, survival and metastatisation.",
keywords = "acid sphingomyelinase, melanoma, microphtalmia- associated transcription factor, signalling mechanisms",
author = "L. Bizzozero and D. Cazzato and D. Cervia and E. Assi and F. Simbari and F. Pagni and {De Palma}, C. and A. Monno and C. Verdelli and Querini, {P. R.} and V. Russo and E. Clementi and C. Perrotta",
year = "2014",
month = "4",
doi = "10.1038/cdd.2013.173",
language = "English",
volume = "21",
pages = "507--520",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway

AU - Bizzozero, L.

AU - Cazzato, D.

AU - Cervia, D.

AU - Assi, E.

AU - Simbari, F.

AU - Pagni, F.

AU - De Palma, C.

AU - Monno, A.

AU - Verdelli, C.

AU - Querini, P. R.

AU - Russo, V.

AU - Clementi, E.

AU - Perrotta, C.

PY - 2014/4

Y1 - 2014/4

N2 - Melanoma is a rapidly growing and highly metastatic cancer with high mortality rates, for which a resolutive treatment is lacking. Identification of novel therapeutic strategies and biomarkers of tumour stage is thus of particular relevance. We report here on a novel biomarker and possible candidate therapeutic target, the sphingolipid metabolising enzyme acid sphingomyelinase (A-SMase). A-SMase expression correlates inversely with tumour stage in human melanoma biopsies. Studies in a mouse model of melanoma and on cell lines derived from mouse and human melanomas demonstrated that A-SMase levels of expression actually determine the malignant phenotype of melanoma cells in terms of pigmentation, tumour progression, invasiveness and metastatic ability. The action of A-SMase is mediated by the activation of the extracellular signal-regulated kinase, the subsequent proteasomal degradation of the Microphtalmia-associated transcription factor (Mitf) and inhibition of cyclin-dependent kinase 2, Bcl-2 and c-Met, downstream targets of Mitf involved in tumour cell proliferation, survival and metastatisation.

AB - Melanoma is a rapidly growing and highly metastatic cancer with high mortality rates, for which a resolutive treatment is lacking. Identification of novel therapeutic strategies and biomarkers of tumour stage is thus of particular relevance. We report here on a novel biomarker and possible candidate therapeutic target, the sphingolipid metabolising enzyme acid sphingomyelinase (A-SMase). A-SMase expression correlates inversely with tumour stage in human melanoma biopsies. Studies in a mouse model of melanoma and on cell lines derived from mouse and human melanomas demonstrated that A-SMase levels of expression actually determine the malignant phenotype of melanoma cells in terms of pigmentation, tumour progression, invasiveness and metastatic ability. The action of A-SMase is mediated by the activation of the extracellular signal-regulated kinase, the subsequent proteasomal degradation of the Microphtalmia-associated transcription factor (Mitf) and inhibition of cyclin-dependent kinase 2, Bcl-2 and c-Met, downstream targets of Mitf involved in tumour cell proliferation, survival and metastatisation.

KW - acid sphingomyelinase

KW - melanoma

KW - microphtalmia- associated transcription factor

KW - signalling mechanisms

UR - http://www.scopus.com/inward/record.url?scp=84903372715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903372715&partnerID=8YFLogxK

U2 - 10.1038/cdd.2013.173

DO - 10.1038/cdd.2013.173

M3 - Article

C2 - 24317198

AN - SCOPUS:84903372715

VL - 21

SP - 507

EP - 520

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

IS - 4

ER -